丽珠集团：JP-1366片注册上市许可申请获受理

Core Viewpoint - Lijun Group has received acceptance from the National Medical Products Administration for the registration of JP-1366 tablets, an innovative potassium ion competitive acid blocker for the treatment of gastroesophageal reflux disease [1] Group 1: Product Development - JP-1366 tablets have shown non-inferior esophageal mucosal healing rates compared to the existing treatment, Lansoprazole, after 8 weeks of administration [1] - The company has completed a Phase III clinical study for JP-1366 tablets, demonstrating significant improvement in symptoms such as heartburn and reflux [1] Group 2: Future Prospects - The injectable formulation of JP-1366 is currently in Phase I clinical trials, targeting the indication of bleeding peptic ulcers [1] - There are currently no P-CAB class injectable drugs available in the global market, indicating a potential market opportunity for the company [1]